BioPharma Dive - Latest News

Rallybio discontinues lead drug for rare maternal disorder

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal blood disorder.

Apr 8, 2025 - 17:04
 0
Rallybio discontinues lead drug for rare maternal disorder

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal blood disorder.

Read More

Tags:

Previous Article

FDA clears vibrating mattress pad to stimulate breathing in premature newborns

Next Article

STAT+: RFK Jr.’s Senate hearing delayed, living with more measles

Related Posts

FTC retains stricter merger guidelines under Trump

FTC retains stricter merger guidelines under Trump

Feb 19, 2025  0

Mineralys shares climb on study data for blood pressure drug

Mineralys shares climb on study data for blood pressure...

Mar 10, 2025  0

Eli Lilly’s earnings, shares lifted by obesity drug sales

Eli Lilly’s earnings, shares lifted by obesity drug sales

Feb 9, 2025  0